David Larwood Archives

FDA Puts Valley Fever Drug on Fast Track

clinical research advantage

A potentially curative anti-Valley Fever drug has been given a boost in its development by the U.S. Food and Drug Administration. The University of Arizona has received word that its request has been granted to designate nikkomycin Z (NikZ) as a “qualifying infectious disease product” (QIDP). NikZ is an antifungal drug that the UA has… Read More →

Arizona bioscience industry producing ‘aha’ moments


AZBio Expo 2014 had “aha moments” at every turn. With over 250 entrepreneurs, innovators, business leaders, legislators, scientists and researchers in attendance, the energy was sizzling and the outlook endless. Here are just a few of the event highlights, appropriately, A to Z: A – Access to Capital is the key. No money. No honey.… Read More →